Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial

被引：0
|
作者：
Zucali, P. A. [1 ]
Simonelli, M. [1 ]
De Vincenzo, F. [1 ]
Fatuzzo, G. [1 ]
Bertossi, M. [1 ]
Perrino, M. [1 ]
Miggiano, C. [1 ]
Giordano, L. [1 ]
Bonifacio, C. [1 ]
Sposta, F. Mrakic [1 ]
Santoro, A. [1 ]
机构：
[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
H18
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [21] Carboplatin-Pemetrexed Combination in Elderly Patients with Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC)
    Vazquez, Sergio
    Carmen Areses, Maria
    Nunez, Natalia F.
    Alonso Herrero, Ana
    Covela Rua, Marta
    Villanueva Silva, Maria J.
    Afonso-Afonso, Francisco J.
    Esquerdo Galiana, Gaspar
    Lazaro Quintela, Martin
    Garcia Mata, Jesus
    Anido Herranz, Urbano
    Casal Rubio, Joaquin
    Firvida Perez, Jose L.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S657 - S657
  • [22] A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.
    Karim, Safiya
    Feld, Ronald
    Leighl, Natasha B.
    Shepherd, Frances A.
    Bradbury, Penelope Ann
    Liu, Geoffrey
    Graham, Donna M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] PEMETREXED/CARBOPLATIN(AC) OR PEMETREXED/CISPLATIN (AP) AS FIRST LINE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA (MPM): TOLERABILITY AND RESPONSE RATE IN OPERABLE PATIENTS
    Pasello, Giulia
    Marulli, Giuseppe
    Nicotra, Samuele
    Rea, Federico
    Loreggian, Lucio
    Bonanno, Laura
    Favaretto, Adolfo
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1367 - S1368
  • [24] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
    G L Ceresoli
    P A Zucali
    M Mencoboni
    M Botta
    F Grossi
    D Cortinovis
    N Zilembo
    C Ripa
    M Tiseo
    A G Favaretto
    H Soto-Parra
    F De Vincenzo
    A Bruzzone
    E Lorenzi
    L Gianoncelli
    B Ercoli
    L Giordano
    A Santoro
    British Journal of Cancer, 2013, 109 : 552 - 558
  • [25] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
    Ceresoli, G. L.
    Zucali, P. A.
    Mencoboni, M.
    Botta, M.
    Grossi, F.
    Cortinovis, D.
    Zilembo, N.
    Ripa, C.
    Tiseo, M.
    Favaretto, A. G.
    Soto-Parra, H.
    De Vincenzo, F.
    Bruzzone, A.
    Lorenzi, E.
    Gianoncelli, L.
    Ercoli, B.
    Giordano, L.
    Santoro, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 552 - 558
  • [27] Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Naito, Yoshiko
    Matsuo, Norikazu
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Ichiki, Masao
    Hoshino, Tomoaki
    ANTICANCER RESEARCH, 2018, 38 (06) : 3779 - 3784
  • [28] Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
    Thein, K.
    Jahan, N.
    Sultan, A.
    Swarup, S.
    Tun, A.
    Yendala, R.
    Ball, S.
    Hlaing, P.
    Htut, T.
    Rehman, S.
    D'Cunha, N.
    Hardwicke, F.
    Tijani, L.
    Awasthi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S472 - S473
  • [29] Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as first-line treatment for elderly patients with advanced non-squamous non-small cell lung cancer
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Naito, Yoshiko
    Matsuo, Norikazu
    Ichiki, Masao
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)
    Spigel, David R.
    Mekhail, Tarek M.
    Waterhouse, David
    Hadley, Terence
    Webb, Charles
    Burris, Howard A.
    Hainsworth, John D.
    Greco, F. Anthony
    CANCER INVESTIGATION, 2017, 35 (08) : 541 - 546
12345